Modra Pharma starts enrolment in Phase II trial of modraDoc006/r for prostate cancer

Netherlands-based oncology drugs developer Modra Pharmaceuticals has started patient enrolment in a Phase II clinical trial of modraDoc006/r to treat patients with metastatic castration-resistant prostate cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news